The effect of sertraline on the pharmacokinetics of desipramine and imipramine

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 2, 1997, Pages 145-156

  Kurtz, Darcie L ^a   Bergstrom, Richard F ^a,b   Goldberg, Mark J ^a   Cerimele, Benito J ^a  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

1-NAPHTHYLAMINE; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DESIPRAMINE; HALF-LIFE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0030770609     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90062-X     Document Type: Article

References (36)

1. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: interactions and therapeutic uses. Br J Psychiatry 1995;167:575-80.
2. Boyer WF, Feighner JP. Pharmacokinetics and drug interactions. In: Feighner JP, Boyer WF, editors. Selective serotonin reuptake inhibitors. Chichester, NY: John Wiley, 1991:81-8.
3. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-6.
4. Maskall DD, Lam RW. Increased plasma concentration of imipramine following augmentation with fluvoxamine [letter]. Am J Psychiatry 1993;150:1566.
5. Seitfritz E, Holsboer-Trachsler E, Hemmeter U. Increased trimipramine plasma levels during fluvoxamine co-medication. Eur Neuropsychopharmacol 1994; 4:15-20.
6. Bell IR, Cole JR. Fluoxetine induces elevation of desipramine levels and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol 1988;8: 447-8.
7. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants [letter]. Am J Psychiatry 1988;145: 1478.
8. Downs JM, Downs AD, Rosenthal TL. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. J Clin Psychiatry 1989;50:226-7.
9. Goodnick PJ. Influence of fluoxetine on plasma levels of desipramine [letter]. Am J Psychiatry 1989;146:552.
10. Preskorn SH, Berber JE, Faul JC, Hirschfeld RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990;147:532.
11. Kahn DC. Increased plasma nortriptyline concentration in a patient co-treated with fluoxetine [letter]. J Clin Psychiatry 1990;51:36.
12. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
13. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
14. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
15. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants [letter]. Am J Psychiatry 1993;150:1125-6.
16. Barros J, Asnis G. An interaction of sertraline and desipramine [letter]. Am J Psychiatry 1993;150:1751.
17. von Moltke L, Greenblatt DJ, Harmatz JS, Shader RI. In vitro inhibition of despramine (DMI) oxidation by fluoxetine (F) and norfluoxetine (NF) is greater than inhibition by sertraline (S) or desmethylsertraline (DS) [abstract]. Clin Pharmacol Ther 1993;53:198.
18. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by erotonin-reuptake inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
19. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
20. Standard analytical protocol 820-0196, imipramine and desipramine in human plasma. West Lafayette, IN: BAS Analytics.
21. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed; vol 2. Cary, NC: SAS Institute, 1989:846.
22. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990;18:346-64.
23. Madsen H, Rasmussen BB, Brøsen K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther 1997;61:319-24.
24. Gray LF, Christiansen J. First-pass metabolism of imipramine in man. Clin Pharmacol Ther 1975;17: 555-63.
25. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
26. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129-41.
27. Gregor KJ, Overhage JM, Coons SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994;16:306-15.
28. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptylinecontrolled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51(12, suppl B):18-27.
29. Zussman BD, Davies CC, Fowles SE, Kumar R, Lang U, Wargenau M, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Presentation to British Pharmacological Society, Brighton, England, December 16, 1994.
30. Jann MW, Carson SW, Grimsley SR, Erikson S, Kumar A, Carter JG. Effects of sertraline (SER) upon imipramine (IMI) pharmacodynamics [abstract]. Clin Pharmacol Ther 1995;57:207.
31. Lennard MS. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 1990;67:273-83.
32. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988;43: 400-6.
33. Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Hum Genet 1993;92:367-72.
34. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
35. Llerena A, Cobaleda J, Martinez C, Benitez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 1996;21:129-38.
36. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome 450IA2. Biochem Pharmacol 1993;45:1211-4.